Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 770.05, up by 54.40 points or 7.60% from its previous closing of Rs. 715.65 on the BSE.

The scrip opened at Rs. 770.00 and has touched a high and low of Rs. 808.15 and Rs. 758.30 respectively. So far 75641 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 877.00 on 06-Mar-2014 and a 52 week low of Rs. 390.00 on 16-May-2013.

Last one week high and low of the scrip stood at Rs. 808.15 and Rs. 701.70 respectively. The current market cap of the company is Rs. 2545.47 crore.

The promoters holding in the company stood at 53.54% while Institutions and Non-Institutions held 22.72% and 23.73% respectively.

The US Supreme Court Chief Justice Roberts has denied Teva’s application for an injunction seeking to prevent launch of a generic version of Copaxone pending the Supreme Court’s decision on Teva’s appeal. This has cleared legal hurdle for Mylan & Natco Pharma to launch the same at market formation. This is the second time that the Chief Justice has denied Teva’s request for such an injunction.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.